ClinicalTrials.gg
CompletedNCT02512900Updated Jun 21, 2017Results posted

A Study to Evaluate the Pharmacokinetics of MEDI9929 (AMG 157) in Adolescents With Mild to Moderate Asthma

A Phase 1 interventional study of MEDI9929, 140 mg in Asthma, sponsored by MedImmune LLC. Completed at 4 sites in Poland. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2017-06-21.

Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
21
Allocation
Not applicable
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing tezepelumab in Asthma — 7 open to participants now, 8 under way, 5 of them phase 3. tezepelumab · Asthma.

Enrollment
24th of 28
21 · median 121
Started
2015
the only one that year
Phase 1
4 of 28
none open now
Registered
3rd of 28
by date
Lead sponsor
2 of 28
MedImmune LLC

Among the 28 studies testing tezepelumab in Asthma, this one is the 24th largest by enrollment, is the only one that started in 2015, is one of 4 in phase 1, and was the 3rd registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

7 of the 28 studies testing tezepelumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About tezepelumab

tezepelumab: first FDA approval 2021 (TEZSPIRE), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing tezepelumab in Asthma, or all of them as a file.
02

Study summary

To evaluate the PK profile of a single-dose of 140 mg subcutaneous (SC) administration of MEDI9929 (AMG 157) in adolescent subjects with mild to moderate asthma.

Read the detailed description

The primary objective is to evaluate the PK profile of a single-dose of 140 mg subcutaneous (SC) administration of MEDI9929 (AMG 157) in adolescent subjects with mild to moderate asthma. The secondary objective is to evaluate the safety and tolerability of MEDI9929 and to evaluate the immunogenicity of MEDI9929 (AMG 157). The exploratory objective is to evaluate the effect of MEDI9929 (AMG 157) on pulmonary function

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Asthma
04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 12 to 17 years (inclusive) at both screening and Day 1.
  • Physician diagnosed asthma for a minimum of 6 months prior to screening.
  • Physician prescribed daily use of asthma controller medication
  • Prebronchodilator of ≥ 70% of predicted normal value at screening.
  • A postbronchodilator increase in FEV1 ≥ 12% and ≥ 200 mL at screening.
  • If on allergen immunotherapy, subjects must be on a stable maintenance dose and schedule ≥ 1 month prior to Visit 1.
  • Weight ≥ 30 kg at both screening and Day 1.
  • for age at both screening and Day 1 that is between 5th and 95th percentile
  • Females of who are sexually active with a nonsterilized male partner must use highly effective from screening
  • Nonsterilized males who are sexually active with a female partner of childbearing potential must use a highly effective method of contraception from screening

Exclusion criteria

Exclusion Criteria:

  • History of a deterioration in asthma that required a burst of systemic within 3 months of screening, up to and including Day 1.
  • Clinical characteristics at either screening or Day 1 that are consistent with uncontrolled asthma as described in GINA guideline.
  • History of hospitalization (overnight admission) for asthma during the 6 months prior to screening.
  • History of intubation for the management of a deterioration in asthma.
  • History of systemic corticosteroid use for the maintenance treatment of asthma within 3 months prior to screening.
  • History of allergy or reaction to any component of the product formulation or history of anaphylaxis following any biologic therapy.
  • Any active medical condition other than asthma, that in the opinion of the investigator and/or medical monitor, may compromise the safety of the subject in the study or interfere with evaluation of the investigational product or reduce the subject's ability to participate in the study (subjects with atopic skin conditions and allergic rhinitis are permitted).
  • Pregnant or breastfeeding females.
  • Current tobacco smoking or cessation of smoking for ≤ 6months prior to screening.
  • Any abnormal findings which in the opinion of the investigator or medical monitor, may compromise the safety of the subject in the study or interfere with evaluation of the investigational product or reduce the subject's ability to participate in the study.
  • Evidence of active liver disease,
  • Positive or virus
  • A positive (HIV) test at screening or subject taking antiretroviral medications
  • Major surgery within 8 weeks prior to Visit 1, or planned in-patient surgery or hospitalization during the study period.
  • History of any known primary immunodeficiency disorder
  • History of a clinically significant infection
  • A helminth parasitic infection within 24 weeks of Visit 1 that has not been treated or has not responded to standard of care therapy.
  • History of cancer.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    MEDI9929, 140 mg, Cohort 1 (12 to 14 years)

    On Day 1, one MEDI9929 subcutaneous injection of 70 mg was given into the anterior aspect of one thigh immediately followed by the second injection of 70 mg into the anterior aspect of the contralateral thigh to make the required dose of 140 mg in participants with 12 to 14 years of age.

    Drug: MEDI9929, 140 mg

  • Experimental
    MEDI9929, 140 mg, Cohort 2 (15 to 17 years)

    On Day 1, one MEDI9929 subcutaneous injection of 70 mg was given into the anterior aspect of one thigh immediately followed by the second injection of 70 mg into the anterior aspect of the contralateral thigh to make the required dose of 140 mg in participants with 15 to 17 years of age.

    Drug: MEDI9929, 140 mg

Interventions

  • On Day 1, two MEDI9929 subcutaneous injection of 70 mg each were given into the anterior aspect of one thigh immediately followed by the second injection into the anterior aspect of the contralateral thigh to make the required dose of 140 mg in participants of 12 to 17 years of age.

    Also known as: Subcutaneous single-dose

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-time Curve From Zero to Infinity (AUC [0-infinity])

    The pharmacokinetic (PK) parameter AUC (0 to infinity) was estimated based on the serum concentrations of MEDI9929. Serum concentrations of MEDI9929 were measured by enzyme-linked immunosorbent assay.

    Time frame: Predose on Day 1 and Day 2, 4, 7, 11, 15, 22, 29, 43, 57 and 85 post-dose.

  2. Area Under the Concentration-Time Curve From Zero to Last Observation (AUC [0-t])

    The PK parameter AUC (0-t) was estimated based on the serum concentrations of MEDI9929. Serum concentrations of MEDI9929 were measured by enzyme-linked immunosorbent assay.

    Time frame: Predose on Day 1 and Day 2, 4, 7, 11, 15, 22, 29, 43, 57 and 85 post-dose.

  3. Dose-normalized AUC (0-infinity) (AUC [0 Infinity]/D)

    The AUC (0-infinity)/D is the area under concentration-time curve extrapolated to infinity postdose normalized by MEDI9929 dose. The PK parameter was estimated based on the serum concentrations of MEDI9929. Serum concentrations of MEDI9929 were measured by enzyme-linked immunosorbent assay.

    Time frame: Predose on Day 1 and Day 2, 4, 7, 11, 15, 22, 29, 43, 57 and 85 post-dose.

  4. Maximum Observed Serum Concentration (Cmax)

    The PK parameter Cmax was estimated based on the serum concentrations of MEDI9929. Serum concentrations of MEDI9929 were measured by enzyme-linked immunosorbent assay.

    Time frame: Predose on Day 1 and Day 2, 4, 7, 11, 15, 22, 29, 43, 57 and 85 post-dose.

  5. Dose-normalized Cmax (Cmax/D)

    The Cmax/D is the maximum observed concentration post dose normalized by MEDI9929 dose. The PK parameter was estimated based on the serum concentrations of MEDI9929. Serum concentrations of MEDI9929 were measured by enzyme-linked immunosorbent assay.

    Time frame: Predose on Day 1 and Day 2, 4, 7, 11, 15, 22, 29, 43, 57 and 85 post-dose.

  6. Time to Reach Cmax (Tmax)

    The Tmax is the time to maximum observed serum concentration of MEDI9929. The PK parameter was estimated based on the serum concentrations of MEDI9929. Serum concentrations of MEDI9929 were measured by enzyme-linked immunosorbent assay.

    Time frame: Predose on Day 1 and Day 2, 4, 7, 11, 15, 22, 29, 43, 57 and 85 post-dose.

  7. Terminal Phase Elimination Half Life (t1/2,z)

    The t½,z is the time measured for the serum drug concentration of MEDI9929 to decrease by one half. The PK parameter was estimated based on the serum concentrations of MEDI9929. Serum concentrations of MEDI9929 were measured by enzyme-linked immunosorbent assay.

    Time frame: Predose on Day 1 and Day 2, 4, 7, 11, 15, 22, 29, 43, 57 and 85 post-dose.

  8. Apparent Clearance (CL/F)

    The PK parameter CL/F was estimated based on the serum concentrations of MEDI9929. Serum concentrations of MEDI9929 were measured by enzyme-linked immunosorbent assay.

    Time frame: Predose on Day 1 and Day 2, 4, 7, 11, 15, 22, 29, 43, 57 and 85 post-dose.

  9. Apparent Steady-state Volume of Distribution (Vss/F)

    The PK parameter Vss/F was estimated based on the serum concentrations of MEDI9929. Serum concentrations of MEDI9929 were measured by enzyme-linked immunosorbent assay.

    Time frame: Predose on Day 1 and Day 2, 4, 7, 11, 15, 22, 29, 43, 57 and 85 post-dose.

Secondary outcomes

  1. Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events

    An adverse event (AE) is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A serious adverse event (SAE) is any AE resulting in any of the following outcomes such as death; initial or prolonged inpatient hospitalization; life-threatening; persistent or significant disability/incapacity; congenital anomaly or birth defect, or is an important medical event that may jeopardize the participant or may require medical intervention to prevent one of the outcomes listed above. A TEAE is defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug. The AEs were summarized using Medical Dictionary for Regulatory Activities version 19.0

    Time frame: From the start of study drug administration up to end of follow-up period, assessed up to Day 85

  2. Treatment-emergent Adverse Events Related to Vital Sign Parameters and Physical Findings

    Vital signs (blood pressure, temperature, pulse, and respiratory rate) were performed throughout the study. The TEAEs related to vital signs in participants were reported.

    Time frame: From the start of study drug administration up to end of follow-up period, assessed up to Day 85

  3. Treatment-emergent Adverse Events Related to Laboratory Parameters

    Laboratory evaluations of blood and urine samples were performed, including hematology (white blood cell count with differential, red blood cell count, hematocrit, hemoglobin and platelet count); serum chemistry: calcium, chloride, potassium, sodium, bicarbonate, aspartate transaminase, alanine transaminase, albumin, uric acid, creatinine, total bilirubin, glucose, alkaline phosphatase, blood urea nitrogen, total protein, and gamma glutamyl transferase; and urinalysis (nitrites, protein, glucose, ketones, urine drug screen, blood, and bilirubin). Number of participants with TEAEs related to laboratory evaluations were reported.

    Time frame: From the start of study drug administration up to end of follow-up period, assessed up to Day 85

  4. Treatment-emergent Adverse Events Related to Electrocardiogram Evaluations

    Computerized triplicate 12-lead ECGs as well as Qualitative 12-lead ECGs were obtained during the study. ECG parameters included heart rate, PR, QRS, QT, and corrected QT (QTc) intervals. Number of participants with TEAEs related to ECG after the start of study drug were to be reported.

    Time frame: From the start of study drug administration up to end of follow-up period, assessed up to Day 85

  5. Number of Participants Positive for Anti-drug Antibodies and With Neutralizing Antibodies for MEDI9929 at Any Visit

    Blood samples for immunogenicity assessment included the determination of anti-drug antibodies (ADA) for MEDI9929. The incidence rate of positive serum antibodies to MEDI9929 were presented.

    Time frame: Days 1 (predose), 29, 57 and 85

07

Results

Posted Feb 23, 2017

Participant flow

Adolescent participants (12 to 17 years, inclusive) with mild to moderate asthma were recruited in an open-label fashion to receive a single-dose of MEDI9929 (also known as tezepelumab or AMG 157) at two study centers in Poland from Sep 2015 to May 2016.

Participant flow — Overall Study
MilestoneMEDI9929, 140 mg, (12 to 14 Years)MEDI9929, 140 mg, (15 to 17 Years)
Started1110
Completed1110
Not completed00

Outcome measures

PrimaryArea Under the Concentration-time Curve From Zero to Infinity (AUC [0-infinity])

The pharmacokinetic (PK) parameter AUC (0 to infinity) was estimated based on the serum concentrations of MEDI9929. Serum concentrations of MEDI9929 were measured by enzyme-linked immunosorbent assay.

Time frame:
Predose on Day 1 and Day 2, 4, 7, 11, 15, 22, 29, 43, 57 and 85 post-dose.
Reported as:
Mean · μg*day/mL
Area Under the Concentration-time Curve From Zero to Infinity (AUC [0-infinity])
μg*day/mLMEDI9929, 140 mg, (12 to 14 Years)MEDI9929, 140 mg, (15 to 17 Years)
Area Under the Concentration-time Curve From Zero to Infinity (AUC [0-infinity])1020 ± 355881 ± 185
PrimaryArea Under the Concentration-Time Curve From Zero to Last Observation (AUC [0-t])

The PK parameter AUC (0-t) was estimated based on the serum concentrations of MEDI9929. Serum concentrations of MEDI9929 were measured by enzyme-linked immunosorbent assay.

Time frame:
Predose on Day 1 and Day 2, 4, 7, 11, 15, 22, 29, 43, 57 and 85 post-dose.
Reported as:
Mean · μg*day/mL
Area Under the Concentration-Time Curve From Zero to Last Observation (AUC [0-t])
μg*day/mLMEDI9929, 140 mg, (12 to 14 Years)MEDI9929, 140 mg, (15 to 17 Years)
Area Under the Concentration-Time Curve From Zero to Last Observation (AUC [0-t])906 ± 284780 ± 171
PrimaryDose-normalized AUC (0-infinity) (AUC [0 Infinity]/D)

The AUC (0-infinity)/D is the area under concentration-time curve extrapolated to infinity postdose normalized by MEDI9929 dose. The PK parameter was estimated based on the serum concentrations of MEDI9929. Serum concentrations of MEDI9929 were measured by enzyme-linked immunosorbent assay.

Time frame:
Predose on Day 1 and Day 2, 4, 7, 11, 15, 22, 29, 43, 57 and 85 post-dose.
Reported as:
Mean · μg*day/mL/mg
Dose-normalized AUC (0-infinity) (AUC [0 Infinity]/D)
μg*day/mL/mgMEDI9929, 140 mg, (12 to 14 Years)MEDI9929, 140 mg, (15 to 17 Years)
Dose-normalized AUC (0-infinity) (AUC [0 Infinity]/D)7.27 ± 2.546.29 ± 1.32
PrimaryMaximum Observed Serum Concentration (Cmax)

The PK parameter Cmax was estimated based on the serum concentrations of MEDI9929. Serum concentrations of MEDI9929 were measured by enzyme-linked immunosorbent assay.

Time frame:
Predose on Day 1 and Day 2, 4, 7, 11, 15, 22, 29, 43, 57 and 85 post-dose.
Reported as:
Mean · μg/mL
Maximum Observed Serum Concentration (Cmax)
μg/mLMEDI9929, 140 mg, (12 to 14 Years)MEDI9929, 140 mg, (15 to 17 Years)
Maximum Observed Serum Concentration (Cmax)24.6 ± 6.6523.4 ± 6.82
PrimaryDose-normalized Cmax (Cmax/D)

The Cmax/D is the maximum observed concentration post dose normalized by MEDI9929 dose. The PK parameter was estimated based on the serum concentrations of MEDI9929. Serum concentrations of MEDI9929 were measured by enzyme-linked immunosorbent assay.

Time frame:
Predose on Day 1 and Day 2, 4, 7, 11, 15, 22, 29, 43, 57 and 85 post-dose.
Reported as:
Mean · μg/mL/mg
Dose-normalized Cmax (Cmax/D)
μg/mL/mgMEDI9929, 140 mg, (12 to 14 Years)MEDI9929, 140 mg, (15 to 17 Years)
Dose-normalized Cmax (Cmax/D)0.176 ± 0.04750.167 ± 0.0487
PrimaryTime to Reach Cmax (Tmax)

The Tmax is the time to maximum observed serum concentration of MEDI9929. The PK parameter was estimated based on the serum concentrations of MEDI9929. Serum concentrations of MEDI9929 were measured by enzyme-linked immunosorbent assay.

Time frame:
Predose on Day 1 and Day 2, 4, 7, 11, 15, 22, 29, 43, 57 and 85 post-dose.
Reported as:
Median · Day
Time to Reach Cmax (Tmax)
DayMEDI9929, 140 mg, (12 to 14 Years)MEDI9929, 140 mg, (15 to 17 Years)
Time to Reach Cmax (Tmax)5.98 (0.990 to 9.97)4.44 (1.40 to 19.9)
PrimaryTerminal Phase Elimination Half Life (t1/2,z)

The t½,z is the time measured for the serum drug concentration of MEDI9929 to decrease by one half. The PK parameter was estimated based on the serum concentrations of MEDI9929. Serum concentrations of MEDI9929 were measured by enzyme-linked immunosorbent assay.

Time frame:
Predose on Day 1 and Day 2, 4, 7, 11, 15, 22, 29, 43, 57 and 85 post-dose.
Reported as:
Mean · Day
Terminal Phase Elimination Half Life (t1/2,z)
DayMEDI9929, 140 mg, (12 to 14 Years)MEDI9929, 140 mg, (15 to 17 Years)
Terminal Phase Elimination Half Life (t1/2,z)24.0 ± 4.0926.7 ± 5.13
PrimaryApparent Clearance (CL/F)

The PK parameter CL/F was estimated based on the serum concentrations of MEDI9929. Serum concentrations of MEDI9929 were measured by enzyme-linked immunosorbent assay.

Time frame:
Predose on Day 1 and Day 2, 4, 7, 11, 15, 22, 29, 43, 57 and 85 post-dose.
Reported as:
Mean · Liter/day
Apparent Clearance (CL/F)
Liter/dayMEDI9929, 140 mg, (12 to 14 Years)MEDI9929, 140 mg, (15 to 17 Years)
Apparent Clearance (CL/F)0.153 ± 0.05070.166 ± 0.0376
PrimaryApparent Steady-state Volume of Distribution (Vss/F)

The PK parameter Vss/F was estimated based on the serum concentrations of MEDI9929. Serum concentrations of MEDI9929 were measured by enzyme-linked immunosorbent assay.

Time frame:
Predose on Day 1 and Day 2, 4, 7, 11, 15, 22, 29, 43, 57 and 85 post-dose.
Reported as:
Mean · Liter
Apparent Steady-state Volume of Distribution (Vss/F)
LiterMEDI9929, 140 mg, (12 to 14 Years)MEDI9929, 140 mg, (15 to 17 Years)
Apparent Steady-state Volume of Distribution (Vss/F)5.65 ± 1.606.55 ± 2.19
SecondaryNumber of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events

An adverse event (AE) is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A serious adverse event (SAE) is any AE resulting in any of the following outcomes such as death; initial or prolonged inpatient hospitalization; life-threatening; persistent or significant disability/incapacity; congenital anomaly or birth defect, or is an important medical event that may jeopardize the participant or may require medical intervention to prevent one of the outcomes listed above. A TEAE is defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug. The AEs were summarized using Medical Dictionary for Regulatory Activities version 19.0

Time frame:
From the start of study drug administration up to end of follow-up period, assessed up to Day 85
Reported as:
Number · Participants
Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events
ParticipantsMEDI9929, 140 mg, (12 to 14 Years)MEDI9929, 140 mg, (15 to 17 Years)
Participants with TEAEs44
Participants with treatment-emergent SAEs00
SecondaryTreatment-emergent Adverse Events Related to Vital Sign Parameters and Physical Findings

Vital signs (blood pressure, temperature, pulse, and respiratory rate) were performed throughout the study. The TEAEs related to vital signs in participants were reported.

Time frame:
From the start of study drug administration up to end of follow-up period, assessed up to Day 85
Reported as:
Number · Participants
Treatment-emergent Adverse Events Related to Vital Sign Parameters and Physical Findings
ParticipantsMEDI9929, 140 mg, (12 to 14 Years)MEDI9929, 140 mg, (15 to 17 Years)
Treatment-emergent Adverse Events Related to Vital Sign Parameters and Physical Findings00
SecondaryTreatment-emergent Adverse Events Related to Laboratory Parameters

Laboratory evaluations of blood and urine samples were performed, including hematology (white blood cell count with differential, red blood cell count, hematocrit, hemoglobin and platelet count); serum chemistry: calcium, chloride, potassium, sodium, bicarbonate, aspartate transaminase, alanine transaminase, albumin, uric acid, creatinine, total bilirubin, glucose, alkaline phosphatase, blood urea nitrogen, total protein, and gamma glutamyl transferase; and urinalysis (nitrites, protein, glucose, ketones, urine drug screen, blood, and bilirubin). Number of participants with TEAEs related to laboratory evaluations were reported.

Time frame:
From the start of study drug administration up to end of follow-up period, assessed up to Day 85
Reported as:
Number · Participants
Treatment-emergent Adverse Events Related to Laboratory Parameters
ParticipantsMEDI9929, 140 mg, (12 to 14 Years)MEDI9929, 140 mg, (15 to 17 Years)
Treatment-emergent Adverse Events Related to Laboratory Parameters00
SecondaryTreatment-emergent Adverse Events Related to Electrocardiogram Evaluations

Computerized triplicate 12-lead ECGs as well as Qualitative 12-lead ECGs were obtained during the study. ECG parameters included heart rate, PR, QRS, QT, and corrected QT (QTc) intervals. Number of participants with TEAEs related to ECG after the start of study drug were to be reported.

Time frame:
From the start of study drug administration up to end of follow-up period, assessed up to Day 85
Reported as:
Number · Participants
Treatment-emergent Adverse Events Related to Electrocardiogram Evaluations
ParticipantsMEDI9929, 140 mg, (12 to 14 Years)MEDI9929, 140 mg, (15 to 17 Years)
Treatment-emergent Adverse Events Related to Electrocardiogram Evaluations00
SecondaryNumber of Participants Positive for Anti-drug Antibodies and With Neutralizing Antibodies for MEDI9929 at Any Visit

Blood samples for immunogenicity assessment included the determination of anti-drug antibodies (ADA) for MEDI9929. The incidence rate of positive serum antibodies to MEDI9929 were presented.

Time frame:
Days 1 (predose), 29, 57 and 85
Reported as:
Number · Participants
Number of Participants Positive for Anti-drug Antibodies and With Neutralizing Antibodies for MEDI9929 at Any Visit
ParticipantsMEDI9929
Baseline: ADA positive, n=211
Baseline: Positive neutralizing antibody, n=10
Post-baseline: ADA positive, n=211
Post-baseline: Positive neutralizing antibody, n=10

Adverse events

Collected over From the start of study drug administration up to end of followup period, assessed up to Day 85.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MEDI9929, 140 mg, (12 to 14 Years)—0/11 (0%)4/11 (36.4%)
MEDI9929, 140 mg, (15 to 17 Years)—0/10 (0%)4/10 (40%)
Most frequent other events
Most frequent other events
EventMEDI9929, 140 mg, (12 to 14 Years)MEDI9929, 140 mg, (15 to 17 Years)
BronchitisInfections and infestations2/110/10
NasopharyngitisInfections and infestations2/111/10
GastritisGastrointestinal disorders0/111/10
Acute sinusitisInfections and infestations0/111/10
PharyngitisInfections and infestations0/111/10
ContusionInjury, poisoning and procedural complications0/111/10
Ligament sprainInjury, poisoning and procedural complications0/111/10
PyrexiaGeneral disorders1/110/10

Baseline characteristics

Age, Continuous
Age, Continuous(Years)MEDI9929, 140 mg, (12 to 14 Years)MEDI9929, 140 mg, (15 to 17 Years)TOTAL
Mean13.5 ± 0.815.9 ± 0.714.7 ± 1.4
Sex: Female, Male
Sex: Female, Male(Participants)MEDI9929, 140 mg, (12 to 14 Years)MEDI9929, 140 mg, (15 to 17 Years)TOTAL
Female156
Male10515
08

Study locations

4 sites
  • Research Site
    Kielce, 25-040, Poland
  • Research Site
    Wrocław, 51-162, Poland
  • Research Site
    Wrocław, 53-201, Poland
  • Research Site
    Łódź, 71-329, Poland
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2015 to primary completion in May 2016, 8 months.

Results were first posted in Feb 2017, 9 months after primary completion.

Of 173 industry-sponsored phase 1 interventional studies under Asthma, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 8 months is above that.

Counting every sponsor, half of 200 studies reached it within 6 months; a quarter within 3 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2015
First posted
Jul 31, 2015
StartActual
Sep 10, 2015
Primary completionActual
May 17, 2016
CompletionActual
May 17, 2016
Results first posted
Feb 23, 2017
Last update
Jun 21, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 21, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02512900
Lead sponsor
MedImmune LLC
Collaborators
Amgen
Responsible party
Sponsor
First posted
Jul 31, 2015
Start date
Sep 10, 2015
Primary completion
May 17, 2016
Completion
May 17, 2016
Results posted
Feb 23, 2017
Last update
Jun 21, 2017

Study contacts

Rene van der Merwe, MBChB, MSc, FFPM
study director · MedImmune LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tezepelumab

Start the discussion